259 related articles for article (PubMed ID: 8221672)
1. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
Davies B; Waxman J; Wasan H; Abel P; Williams G; Krausz T; Neal D; Thomas D; Hanby A; Balkwill F
Cancer Res; 1993 Nov; 53(22):5365-9. PubMed ID: 8221672
[TBL] [Abstract][Full Text] [Related]
2. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
3. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Yoshida O
J Urol; 1999 Apr; 161(4):1359-63. PubMed ID: 10081908
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer.
Papathoma AS; Petraki C; Grigorakis A; Papakonstantinou H; Karavana V; Stefanakis S; Sotsiou F; Pintzas A
Anticancer Res; 2000; 20(3B):2009-13. PubMed ID: 10928143
[TBL] [Abstract][Full Text] [Related]
5. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
6. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder.
Sumi T; Yoshida H; Hyun Y; Yasui T; Matsumoto Y; Hattori K; Sugimura K; Kawashima H; Nakatani T; Ishiko O
Oncol Rep; 2003; 10(2):345-9. PubMed ID: 12579270
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer.
Liabakk NB; Talbot I; Smith RA; Wilkinson K; Balkwill F
Cancer Res; 1996 Jan; 56(1):190-6. PubMed ID: 8548762
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver.
Milani S; Herbst H; Schuppan D; Grappone C; Pellegrini G; Pinzani M; Casini A; Calabró A; Ciancio G; Stefanini F
Am J Pathol; 1994 Mar; 144(3):528-37. PubMed ID: 8129038
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer.
Impola U; Uitto VJ; Hietanen J; Hakkinen L; Zhang L; Larjava H; Isaka K; Saarialho-Kere U
J Pathol; 2004 Jan; 202(1):14-22. PubMed ID: 14694517
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.
Seargent JM; Loadman PM; Martin SW; Naylor B; Bibby MC; Gill JH
Urology; 2005 Apr; 65(4):815-20. PubMed ID: 15833553
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
17. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
[TBL] [Abstract][Full Text] [Related]
18. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.
Kitagawa Y; Kunimi K; Ito H; Sato H; Uchibayashi T; Okada Y; Seiki M; Namiki M
J Urol; 1998 Oct; 160(4):1540-5. PubMed ID: 9751409
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
